[Silymarin in pregnancy and during hormonal contraceptive treatment. Blood chemistry and ultrastructural findings in the experimental model].
Further systematic study of the relation between drugs and the ultrastructure of the liver is reported with regard to the experimental administration of silimarin to pregnant women and others on the pill. Marked signs of ultrastructural alteration of the REL and biliary cell pole were noted, matched, by evidence of throbophilia and changes in protein activity and lipid synthesis, are noted in these situations, but not when suitable doses of silimarine are taken with the pill. It is suggested that silimarin may prevent and correct liver damage during pregnancy and the administration of oestroprogestins.
D000818:Animals; D003276:Contraceptives, Oral / Q000494:pharmacology*; D005260:Female; D005419:Flavonoids / Q000627:therapeutic use*; D007565:Jaundice / Q000188:drug therapy; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects*; D008107:Liver Diseases / Q000188:drug therapy*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011517:Prothrombin Time; D011817:Rabbits; D012838:Silymarin / Q000494:pharmacology / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D003276:Contraceptives, Oral; D005419:Flavonoids; D008055:Lipids; D012838:Silymarin; D014280:Triglycerides
La silimarina in gravidanza e nel trattamento contraccettivo ormonale. Rilievi ematochimici ed ultrastrutturali su modello sperimentale.